title: Temocillin in cystic fibrosis: a retrospective pilot study.
abstract: BACKGROUND
  Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.
  
  
  METHODS
  A retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within +/-1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV(1)%, FVC%).
  
  
  RESULTS
  Twenty six patients had received temocillin. Baseline values of FEV(1)% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV(1)% increased by 7.12(11.67)% after TIV (p<0.01) and 6.65(7.62)% after NTIV (p<0.01). There was no significant difference between the IV courses in mean %change in lung function TIV versus NTIV (FEV(1) 0.46% [95%CI: -4.55 to 5.48%]).
  
  
  CONCLUSIONS
  These data suggest equivalence in the lung function outcome of IV antibiotic therapy includingtemocillin versus standard IV antibiotic therapy.
authors.affiliation: Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, Northern Ireland, United Kingdom.
authors.forename: Lisa
authors.initials: L
authors.lastname: Kent
authors.forename: Judy M
authors.initials: JM
authors.lastname: Bradley
authors.forename: Megan
authors.initials: M
authors.lastname: France
authors.forename: Gerd
authors.initials: G
authors.lastname: Döring
authors.forename: Stéphane
authors.initials: S
authors.lastname: Carryn
authors.forename: Ian
authors.initials: I
authors.lastname: Bradbury
authors.forename: Jackie
authors.initials: J
authors.lastname: Rendall
authors.forename: Andrew
authors.initials: A
authors.lastname: Jones
authors.forename: J Stuart
authors.initials: JS
authors.lastname: Elborn
mesh_terms: D000328:Adult; D000617:Aminoglycosides / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D019121:Burkholderia Infections / Q000188:drug therapy* / Q000209:etiology; D016956:Burkholderia cepacia; D015331:Cohort Studies; D018592:Cross-Over Studies; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010406:Penicillins / Q000008:administration & dosage*; D010865:Pilot Projects; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D011550:Pseudomonas aeruginosa; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D010406:Penicillins; C031367:temocillin